The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global microbiome sequencing services market size reached US$ 1,537.3 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 4,612.0 Million by 2027, exhibiting a growth rate (CAGR) of 20.2% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Microbiome sequencing services help determine the function of the microbiome in human health and disease pathogenesis using next-generation sequencing (NGS) instruments. These services provide comprehensive bioinformatics and statistical analyses in a user-friendly and interactive report. They also offer faster and more accurate classification as compared to traditional identification methods like cloning and culturing. They mainly include functional profiling, clustering heatmap, alpha-diversity, beta-diversity, LEfSe biomarker discovery, and taxa, antibiotics resistance gene and virulence factor identification. At present, microbiome sequencing services are gaining traction across the globe.
The burgeoning pharmaceutical sector represents one of the key factors strengthening the market growth. Apart from this, there is a considerable rise in the prevalence of colorectal cancer (CRC) on account of the growing number of individuals with inflammatory intestinal conditions, the increasing geriatric population, and the rising consumption of low fiber and high-fat diets. As a result, the demand for early disease detection and diagnosis is escalating around the world. This, coupled with the wide applications of microbiome sequencing services in academia and research institutes for protein and small molecule analysis, is positively influencing the market. Furthermore, leading market players are utilizing advanced technologies, including engineered organoids derived from human stem cells, high-throughput culturing, and micro fluids that assist in improving the efficiency and quality of microbiome research. They are also focusing on customizing gut microbial consortia to develop advanced individualized medicine. Besides this, due to the faster and cost-effective sequencing platforms and data analysis pipelines, microbiome content is widely being used as a biomarker for different diseases. Other major factors, including increasing genomic research and rising healthcare expenditure, are anticipated to stimulate the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global microbiome sequencing services market report, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on technology, research type, laboratory type, application and end user.
Breakup by Technology:
Breakup by Research Type:
Breakup by Laboratory Type:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being BaseClear B.V., Clinical-Microbiomics A/S, Diversigen Inc (OraSure Technologies Inc.), Mérieux NutriSciences, Metabiomics Corporation (BioSpherex LLC), Microbiome Insights Inc., Microbiome Therapeutics LLC, Molecular Research LP, Molzym GmbH & Co. KG, Resphera Biosciences LLC, Shanghai Realbio Technology (RBT) Co. Ltd. and Zymo Research Corporation.
|Base Year of the Analysis||2021|
|Segment Coverage||Technology, Research Type, Laboratory Type, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||BaseClear B.V., Clinical-Microbiomics A/S, Diversigen Inc (OraSure Technologies Inc.), Mérieux NutriSciences, Metabiomics Corporation (BioSpherex LLC), Microbiome Insights Inc., Microbiome Therapeutics LLC, Molecular Research LP, Molzym GmbH & Co. KG, Resphera Biosciences LLC, Shanghai Realbio Technology (RBT) Co. Ltd. and Zymo Research Corporation|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at